SCHEMBL4773316

SCHEMBL4773316

[CH2]CC(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.69
MAPK1 P28482 1/20 0.69
HIF1A Q16665 1/20 0.69
ERCC5 P28715 2/20 0.61
FEN1 P39748 2/20 0.61
TSHR P16473 1/20 0.59
CASP1 P29466 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
KDM4E B2RXH2 1/20 0.56
MAPT P10636 1/20 0.56
POLB P06746 3/20 0.51
HPGD P15428 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.49
THRB P10828 1/20 0.49
RECQL P46063 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
CYP3A4 P08684 1/20 0.47
SRD5A2 P31213 1/20 0.47
AGTR1 P30556 2/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1691536 0.82 ALDH1A1 (1.00) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL5253911 0.82 ALDH1A1 (0.71) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL5253915 0.82 ALDH1A1 (0.71) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL29481555 0.82 ALDH1A1 (1.00) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL641759 0.80 ALDH1A1 (0.69) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL30839507 0.80 ALDH1A1 (0.69) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL29712843 0.80 ALDH1A1 (0.69) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL435407 0.80 ALDH1A1 (0.69) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL14325064 0.80 ALDH1A1 (0.69) ALDH1A1MAPK1HIF1AERCC5FEN1
SCHEMBL29859075 0.80 ALDH1A1 (0.69) ALDH1A1MAPK1HIF1AERCC5FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed